Charles Schwab Investment Management Inc. Grows Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Charles Schwab Investment Management Inc. increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 1.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,006,935 shares of the biotechnology company’s stock after purchasing an additional 12,574 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Arrowhead Pharmaceuticals were worth $19,504,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ARWR. Fifth Third Bancorp grew its position in shares of Arrowhead Pharmaceuticals by 42.5% during the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after buying an additional 354 shares in the last quarter. Values First Advisors Inc. purchased a new position in Arrowhead Pharmaceuticals in the third quarter worth approximately $52,000. Meeder Asset Management Inc. grew its holdings in Arrowhead Pharmaceuticals by 4,629.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 3,333 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at approximately $96,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 788 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Up 5.9 %

Shares of NASDAQ:ARWR opened at $23.61 on Friday. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The stock has a market cap of $2.94 billion, a P/E ratio of -4.70 and a beta of 0.91. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $17.05 and a 1-year high of $39.83. The firm has a fifty day moving average price of $20.61 and a 200 day moving average price of $23.22.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. B. Riley reissued a “buy” rating and issued a $55.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. Royal Bank of Canada reissued an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. HC Wainwright boosted their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Citigroup dropped their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $42.70.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.